CD274 and neoplasm: Because our in vitro experiments indicated that NExT can target tumor cells through the disruption of the PD1/PDL1 axis (Fig. 3g-i), we further confirmed the PDL1 levels in tumor cells and the TME in the PDX tumor tissue.